What is Moravek?
Moravek, Inc. stands as a distinguished leader in the production of high-quality radiolabeled and stable-labeled compounds. The company specializes in GMP carbon-14 labeled active pharmaceutical ingredients (APIs), crucial for early-phase clinical trials. With a legacy spanning over 45 years, Moravek offers comprehensive custom synthesis, purification, and analytical services tailored to the needs of global pharmaceutical companies and research institutions. Their extensive product catalog features a wide array of isotopically labeled compounds, ensuring adherence to stringent regulatory standards. Moravek's reputation is built on a foundation of a rigorous quality system and an unwavering commitment to client satisfaction within the pharmaceutical and research communities.
How much funding has Moravek raised?
Moravek has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Moravek?
The recent large-scale, late-stage funding infusion positions Moravek for accelerated growth and expanded operational capabilities. This strategic capital injection is expected to bolster the company's capacity for custom synthesis and the development of novel radiolabeled compounds, further solidifying its market leadership. Moravek is poised to enhance its service offerings, potentially investing in advanced manufacturing technologies and broadening its research collaborations. The company's trajectory suggests a continued focus on supporting critical pharmaceutical research and clinical trial advancements, leveraging this investment to drive innovation and meet the evolving demands of the life sciences industry.
See full Moravek company page
